New combo drug study seeks clues to fight solid tumors
NCT ID NCT06651593
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will receive the treatment, and the main goal is to track safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSATELLITE STABLE COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer